Methods for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre research programme including ELUCIDATE RCT

Peter J Selby, ^{1,2}* Rosamonde E Banks,¹ Walter Gregory,³ Jenny Hewison,⁴ William Rosenberg,⁵ Douglas G Altman,⁶ Jonathan J Deeks,⁷ Christopher McCabe,⁸ Julie Parkes,⁹ Catharine Sturgeon,¹⁰ Douglas Thompson,² Maureen Twiddy,⁴ Janine Bestall,⁴ Joan Bedlington,¹¹ Tilly Hale,^{11†} Jacqueline Dinnes,⁷ Marc Jones,³ Andrew Lewington,² Michael P Messenger,² Vicky Napp,³ Alice Sitch,⁷ Sudeep Tanwar,⁵ Naveen S Vasudev,^{1,2} Paul Baxter,¹² Sue Bell,³ David A Cairns,¹ Nicola Calder,² Neil Corrigan,³ Francesco Del Galdo,¹³ Peter Heudtlass,³ Nick Hornigold,¹ Claire Hulme,⁴ Michelle Hutchinson,¹ Carys Lippiatt,¹⁴ Tobias Livingstone,² Roberta Longo,⁴ Matthew Potton,³ Stephanie Roberts,¹ Sheryl Sim,¹ Sebastian Trainor,¹ Matthew Welberry Smith,^{1,2} James Neuberger,¹⁵ Douglas Thorburn,¹⁶ Paul Richardson,¹⁷ John Christie,¹⁸ Neil Sheerin,¹⁹ William McKane,²⁰ Paul Gibbs,²¹ Anusha Edwards,²² Naeem Soomro,¹⁹ Adebanji Adeyoju,²³ Grant D Stewart^{24,25} and David Hrouda²⁶

¹Clinical and Biomedical Proteomics Group, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK

²Leeds Teaching Hospitals NHS Trust, Leeds, UK

³Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK ⁴Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

⁵Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK

⁶Centre for Statistics in Medicine, University of Oxford, Oxford, UK ⁷Institute of Applied Health Research, University of Birmingham, Birmingham, UK ⁸Department of Emergency Medicine, University of Alberta Hospital, Edmonton, AB, Canada ⁹Primary Care and Population Sciences Academic Unit, University of Southampton, Southampton, UK ¹⁰Royal Infirmary of Edinburgh, Edinburgh, UK ¹¹LIVErNORTH Liver Patient Support, Newcastle upon Tyne, UK ¹²Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK ¹³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK ¹⁴Department of Specialist Laboratory Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK ¹⁵University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK ¹⁶Royal Free London NHS Foundation Trust, London, UK ¹⁷Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK ¹⁸Royal Devon and Exeter NHS Foundation Trust, Exeter, UK ¹⁹Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK ²⁰Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK ²¹Portsmouth Hospitals NHS Trust, Portsmouth, UK ²²North Bristol NHS Trust, Bristol, UK ²³Stockport NHS Foundation Trust, Stockport, UK ²⁴NHS Lothian, Edinburgh, UK ²⁵Academic Urology Group, University of Cambridge, Cambridge, UK ²⁶Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK

*Corresponding author p.j.selby@leeds.ac.uk †In memoriam

Declared competing interests of authors: Peter J Selby has an international patent (application no. PCT/ GB2014/050768; biomarker; University of Leeds) issued. Rosamonde E Banks reports grants from various non-commercial funding sources during the conduct of the study; in addition, she has a international patent (application no. PCT/GB2014/050768; biomarker; University of Leeds) issued. Jenny Hewison is a panel member of the National Institute for Health Research (NIHR) Clinical Trials Unit Standing Advisory Committee. Grant D Stewart has a patent (1408091.5) pending to the Medical Research Council (MRC) Human Genetics Unit (HGU). James Neuberger is a consultant to Astellas Pharma, Inc., and has received speaker support funding from Astellas and Novartis UK. Claire Hulme has received grants from the NIHR during the conduct of the study and is a panel member of the Health Technology Assessment (HTA) Commissioning Board. Andrew Lewington has received personal fees from Fresenius Medical Care, Baxter Healthcare Ltd, AM-Pharma, BioPorto Diagnostics A/S and GE Healthcare, outside the submitted work; in addition, he has a patent (ACY-1 biomarker) pending. Naveen S Vasudev has received personal fees from Bristol-Myers Squibb and GlaxoSmithKline plc, outside the submitted work. William Rosenberg was an inventor of the enhanced liver fibrosis (ELF) test when he was an employee of the University of Southampton. His rights were transferred to Siemens Healthcare Diagnostics Ltd by the University of Southampton. He does not receive any payment in relation to sales of the test by the manufacturer Siemens Helathcare Diagnostics. He has received grant support and speaker fees from Siemens Healthcare Diagnostics and is a director of iQur Ltd (Southampton, UK), a company that provides ELF testing.

In the context of this NIHR-funded study, all ELF testing provided by iQur Ltd was performed on a not-for-profit, cost-recovery basis. William Rosenberg is married to Julie Parkes, who is a co-investgator on the programme. Julie Parkes reports receiving support from the Speakers' Bureau for Siemens Healthcare Diagnostics, outside the submitted work, and is married to William Rosenberg (co-applicant). Jonathan J Deeks is a panel member of the HTA Commissioning Board.

Published June 2018 DOI: 10.3310/pgfar06030

Plain English summary

Evaluation of biomarkers in patients with kidney and liver diseases Programme Grants for Applied Research 2018; Vol. 6: No. 3 DOI: 10.3310/pgfar06030

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Plain English summary

Protein biomarkers are substances that can be measured, often in body fluids, to provide information about patients and their illness. Measuring biomarkers in blood or urine is simple and safe and may help diagnose disease and its severity and help choose treatment. New research is discovering more biomarkers but there is no quick way to decide how useful they are.

Our research was aimed at methods to assess the clinical usefulness of biomarkers as quickly and efficiently as possible:

- We identified the best research methods for monitoring disease or treatment with biomarkers. We showed that the literature is modest in scale and of variable quality. We made recommendations for improvements.
- We created a sample 'banking' system for collecting and storing patient samples and relevant clinical data from large numbers of patients, for renal cell carcinoma and renal transplantation. Biomarkers were identified and analysed and the system was used to show their value.
- We conducted a trial of the 'enhanced liver fibrosis' test in 878 patients. We showed that it alters patient care but longer follow-up is needed to show if this results in improvements in long-term outcomes.

Our experience is part of the basis of a new framework for evaluating diagnostic tests in four centres in England.

Programme Grants for Applied Research

ISSN 2050-4322 (Print)

ISSN 2050-4330 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Programme Grants for Applied Research journal

Reports are published in *Programme Grants for Applied Research* (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Programme Grants for Applied Research programme

The Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.

The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.

For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-for-applied-research.htm

This report

The research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0707-10101. The contractual start date was in January 2009. The final report began editorial review in February 2016 and was accepted for publication in June 2017. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PGfAR programme or the Department of Health and Social Care.

© Queen's Printer and Controller of HMSO 2018. This work was produced by Selby *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

NIHR Journals Library Editor-in-Chief

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Dr Catriona McDaid Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk